STOCK TITAN

[SCHEDULE 13G] CS DIAGNOSTICS CORP. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Thomas Graus filed a Schedule 13G reporting beneficial ownership of 13,392,434 shares of CS Diagnostics Corp. common stock, equal to 9.9% of the class as of the filing. The holding comprises 3,700,000 shares held directly and 9,692,434 shares issuable upon conversion of Series B preferred shares, although conversions are limited by a 9.9% cap in the Certificate of Designation. The filing states sole voting and dispositive power over the reported shares and excludes any securities held through entities where the filer lacks control. The filer certifies the stake was not acquired to change or influence control.

Thomas Graus ha depositato una Schedule 13G che riporta la proprietà beneficiaria di 13.392.434 azioni ordinarie di CS Diagnostics Corp., pari a 9,9% della classe al momento della presentazione. La partecipazione è composta da 3.700.000 azioni detenute direttamente e 9.692.434 azioni imponibili al momento della conversione delle azioni privilegiate di Serie B, anche se le conversioni sono limitate da un tetto del 9,9% nel Certificate of Designation. La presentazione indica potere di voto e dispositivi esclusivi sui titoli riportati e esclude eventuali titoli detenuti tramite entità dove il dichiarante non ha controllo. Il dichiarante certifica che la partecipazione non è stata acquisita per cambiare o influenzare il controllo.

Thomas Graus presentó un Schedule 13G que reporta la propiedad beneficiaria de 13,392,434 acciones ordinarias de CS Diagnostics Corp., equivalente a 9,9% de la clase al momento de la presentación. La participación comprende 3,700,000 acciones poseídas directamente y 9,692,434 acciones susceptibles de ser emitidas tras la conversión de las acciones preferentes de Serie B, aunque las conversiones están limitadas por un tope del 9,9% en el Certificate of Designation. La presentación indica poder de voto y de disposición exclusivo sobre las acciones declaradas y excluye cualquier valor mantenido a través de entidades donde el solicitante no tiene control. El solicitante certifica que la participación no fue adquirida para cambiar o influir en el control.

Thomas Graus는 CS Diagnostics Corp. 일반 주식의 수혜 귀속을 보고하는 Schedule 13G를 제출했으며, 보유 주식 수는 13,392,434주로서 당 시의 9.9%에 해당합니다. 보유는 직접 보유 3,700,000주와 시리즈 B 우선주의 전환으로 얻을 수 있는 9,692,434주로 구성되며, 전환은 Certificate of Designation의 한도인 9.9%로 제한됩니다. 제출 문서는 보고된 주식에 대한 단독 의결권과 처분권을 명시하고, 발행인이 지배권을 행사하지 않는 법인 등을 통해 보유한 모든 증권은 제외합니다. 제출자는 이 지분이 지배권을 바꾸거나 영향을 주기 위해 취득된 것이 아님을 인증합니다.

Thomas Graus a déposé un Schedule 13G indiquant la propriété bénéficiaire de 13,392,434 actions ordinaires de CS Diagnostics Corp., soit 9,9% de la catégorie au moment du dépôt. La participation se compose de 3,700,000 actions détenues directement et 9,692,434 actions susceptibles d'être émises lors de la conversion des actions privilégiées de série B, bien que les conversions soient limitées par un plafond de 9,9% dans le Certificate of Designation. Le dossier indique un pouvoir de vote et de disposition exclusif sur les actions déclarées et exclut tout titre détenu par des entités sur lesquelles le déposant n'a pas de contrôle. Le déposant certifie que la participation n'a pas été acquise dans le but de changer ou d'influencer le contrôle.

Thomas Graus hat ein Schedule 13G eingereicht, das die wirtschaftlich Berechtigten an 13.392.434 Stammaktien der CS Diagnostics Corp. meldet, was 9,9% der Klasse zum Zeitpunkt der Einreichung entspricht. Das Halten umfasst 3.700.000 Aktien, die direkt gehalten werden, sowie 9.692.434 Aktien, die durch die Umwandlung von Series-B-Vorzugsaktien ausgegeben werden können, wobei Konversionen jedoch durch eine 9,9% Deckelung im Designation Certificate eingeschränkt sind. Die Einreichung gibt alleinige Stimm- und Verfügungsgewalt über die berichteten Aktien an und schließt Wertpapiere, die über Gesellschaften gehalten werden, über die der Einreicher keine Kontrolle hat, aus. Der Einreicher bestätigt, dass der Anteil nicht erworben wurde, um die Kontrolle zu verändern oder zu beeinflussen.

Thomas Graus قد قدّم Schedule 13G يُبلغ عن الملكية المستفيدة لــ 13,392,434 أسهم عادية من CS Diagnostics Corp.، مساوية لـ 9.9% من الفئة عند التقديم. تتألف الحيازة من 3,700,000 سهمًا مملوكًا بشكل مباشر و9,692,434 سهمًا يمكن إصدارها عند تحويل أسهم تفضيلية من الفئة B، على الرغم من أن التحويلات مقيدة بحد أقصى 9.9% في شهادة التعيين. تنص الإيداع على سلطة تصويت وتصرّف حصرية على الأسهم المبلغ عنها، وتستثني أي أوراق مالية مملوكة من خلال كيانات ليس لدى المقدم للطلب سيطرة عليها. يشهد المقدم أن الحصة لم تُكتسب بهدف تغيير أو التأثير على السيطرة.

Thomas Graus 提交了 Schedule 13G,报告 CS Diagnostics Corp.普通股的实际拥有情况,共 13,392,434 股,约占公司类别的9.9%。该持股由直接持有的3,700,000股以及可通过对 Series B 优先股的转换取得的 9,692,434 股组成,尽管转换受证书指定中的 9.9% 限制。申报显示对所报告股票拥有单独的投票权和处置权,并排除通过发起人缺乏控制的实体所持有的任何证券。申报人证明该持股并非为改变或影响控制权而获取。

Positive
  • None.
Negative
  • None.

Insights

Insider holds a near‑cap position: 13.39M shares (9.9%).

The reported stake is a mix of direct common stock and convertible Series B preferred shares, with conversion limited to avoid exceeding 9.9% ownership. The filer reports sole voting and sole dispositive power for the full reported amount, which is material for shareholder voting calculations.

Key dependencies include the Certificate of Designation cap and the outstanding share count used to compute the 9.9% figure; any change in outstanding shares or conversion terms would alter the percent ownership. Watch for filings or amendments if conversion limitations change or if additional Series B shares are issued within the cap.

Control implications are limited despite large economic stake.

The filing notes that Preferred A shares carry supervoting rights that concentrate >90% of voting power with their holder, and therefore the reported holder does not claim de facto control. This distinguishes economic ownership from control and affects corporate governance dynamics.

Investors should note the certification that the position was not acquired to influence control and monitor any future amendments, Schedule 13D filings, or changes to voting structures that could indicate a shift from passive to active intent within a short timeframe.

Thomas Graus ha depositato una Schedule 13G che riporta la proprietà beneficiaria di 13.392.434 azioni ordinarie di CS Diagnostics Corp., pari a 9,9% della classe al momento della presentazione. La partecipazione è composta da 3.700.000 azioni detenute direttamente e 9.692.434 azioni imponibili al momento della conversione delle azioni privilegiate di Serie B, anche se le conversioni sono limitate da un tetto del 9,9% nel Certificate of Designation. La presentazione indica potere di voto e dispositivi esclusivi sui titoli riportati e esclude eventuali titoli detenuti tramite entità dove il dichiarante non ha controllo. Il dichiarante certifica che la partecipazione non è stata acquisita per cambiare o influenzare il controllo.

Thomas Graus presentó un Schedule 13G que reporta la propiedad beneficiaria de 13,392,434 acciones ordinarias de CS Diagnostics Corp., equivalente a 9,9% de la clase al momento de la presentación. La participación comprende 3,700,000 acciones poseídas directamente y 9,692,434 acciones susceptibles de ser emitidas tras la conversión de las acciones preferentes de Serie B, aunque las conversiones están limitadas por un tope del 9,9% en el Certificate of Designation. La presentación indica poder de voto y de disposición exclusivo sobre las acciones declaradas y excluye cualquier valor mantenido a través de entidades donde el solicitante no tiene control. El solicitante certifica que la participación no fue adquirida para cambiar o influir en el control.

Thomas Graus는 CS Diagnostics Corp. 일반 주식의 수혜 귀속을 보고하는 Schedule 13G를 제출했으며, 보유 주식 수는 13,392,434주로서 당 시의 9.9%에 해당합니다. 보유는 직접 보유 3,700,000주와 시리즈 B 우선주의 전환으로 얻을 수 있는 9,692,434주로 구성되며, 전환은 Certificate of Designation의 한도인 9.9%로 제한됩니다. 제출 문서는 보고된 주식에 대한 단독 의결권과 처분권을 명시하고, 발행인이 지배권을 행사하지 않는 법인 등을 통해 보유한 모든 증권은 제외합니다. 제출자는 이 지분이 지배권을 바꾸거나 영향을 주기 위해 취득된 것이 아님을 인증합니다.

Thomas Graus a déposé un Schedule 13G indiquant la propriété bénéficiaire de 13,392,434 actions ordinaires de CS Diagnostics Corp., soit 9,9% de la catégorie au moment du dépôt. La participation se compose de 3,700,000 actions détenues directement et 9,692,434 actions susceptibles d'être émises lors de la conversion des actions privilégiées de série B, bien que les conversions soient limitées par un plafond de 9,9% dans le Certificate of Designation. Le dossier indique un pouvoir de vote et de disposition exclusif sur les actions déclarées et exclut tout titre détenu par des entités sur lesquelles le déposant n'a pas de contrôle. Le déposant certifie que la participation n'a pas été acquise dans le but de changer ou d'influencer le contrôle.

Thomas Graus hat ein Schedule 13G eingereicht, das die wirtschaftlich Berechtigten an 13.392.434 Stammaktien der CS Diagnostics Corp. meldet, was 9,9% der Klasse zum Zeitpunkt der Einreichung entspricht. Das Halten umfasst 3.700.000 Aktien, die direkt gehalten werden, sowie 9.692.434 Aktien, die durch die Umwandlung von Series-B-Vorzugsaktien ausgegeben werden können, wobei Konversionen jedoch durch eine 9,9% Deckelung im Designation Certificate eingeschränkt sind. Die Einreichung gibt alleinige Stimm- und Verfügungsgewalt über die berichteten Aktien an und schließt Wertpapiere, die über Gesellschaften gehalten werden, über die der Einreicher keine Kontrolle hat, aus. Der Einreicher bestätigt, dass der Anteil nicht erworben wurde, um die Kontrolle zu verändern oder zu beeinflussen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Pursuant to the Certificate of Designation for the Series B Preferred Stock the Reporting Person may not convert any shares if such conversion would result in the Reporting Person beneficially owning more than 9.9 percent of the outstanding Common Stock The number of shares of Common Stock reported as beneficially owned reflects this limitation In addition the issuers Preferred A Shares carry supervoting rights exceeding 90 percent of total voting power effectively providing their holder with control of the issuer therefore the Reporting Person does not possess de facto control of the issuer All percentages reported herein are approximate and have been calculated based on the issuers reported outstanding shares subject to the 9.9 percent ownership limitation applicable to the Series B Preferred Stock pursuant to its Certificate of Designation The beneficial ownership reported herein excludes any shares of the issuers securities that may be beneficially owned by any entity in which the Reporting Person holds a noncontrolling equity interest as the Reporting Person does not have or share voting or dispositive power over such securities


SCHEDULE 13G



Graus Thomas
Signature:/s/ Graus Thomas
Name/Title:Mr.
Date:10/06/2025

FAQ

What stake does Thomas Graus report in CS Diagnostics (CSDX)?

The filing reports beneficial ownership of 13,392,434 shares, representing 9.9% of the common stock.

How is the 13,392,434‑share total composed?

It comprises 3,700,000 shares held directly and 9,692,434 shares issuable upon conversion of Series B preferred stock, subject to a 9.9% conversion cap.

Does the filer claim voting control over CS Diagnostics (CSDX)?

The filer reports sole voting and dispositive power over the reported shares but states they do not possess de facto control due to Preferred A supervoting rights held by another holder.

Was the position acquired to influence control of the company?

No. The filing includes a certification that the securities were not acquired and are not held to change or influence control.

Are there limitations on converting the Series B preferred shares?

Yes. The Certificate of Designation limits conversions so the reporting person cannot beneficially own more than 9.9% of outstanding common stock.
CS Diagnostics

OTC:CSDX

CSDX Rankings

CSDX Latest News

CSDX Latest SEC Filings

CSDX Stock Data

20.61M
Medical Devices
Healthcare
Link
Germany
Neuss